Galapagos - Model GLPG3667 - Reversible and Selective TYK2 Inhibitor
A TYK2 inhibitor for which topline results from the Phase 1b in psoriasis were reported in July 2021. Phase 2 studies in dermatomyositis and Systemic Lupus Erythematosus (SLE) are expected to start in 2023.
-
Most popular related searches
GLPG3667 was generally well tolerated in this tria...
GLPG3667 was generally well tolerated in this trial. At week 4, four out of 10 patients in the high dose group had a PASI 50 response, compared to one out of 10 subjects on placebo. There were no subjects with a PASI 50 response on the low dose of GLPG3667. The four responders in the high dose group of GLPG3667 achieved a 52%, 65%, 74% and 81% improvement respectively in their PASI scores from baseline, while the subject randomized to placebo improved by 52%. Positive efficacy signals were also observed with the high dose for other endpoints, including affected Body Surface Area and physician and patient global assessment, versus placebo at week 4. For more information, please see our press release on 14 July 2021.
We plan to initiate a Phase 2 program with GLPG3667 in 2022.
Customer reviews
No reviews were found for Galapagos - Model GLPG3667 - Reversible and Selective TYK2 Inhibitor. Be the first to review!